The Investor's Podcast on $NVO

The Investor's Podcast has discussed $NVO in 1 video since 2026-10-31. The latest, on 2026-10-31, was bullish.

2026-10-31Bullish
“S&P Global (SPGI), Novo Nordisk (NVO), Deckers (DECK) | Stock Analysis & Valuation (TIP857)”
AI summary · Bullish on NVO: at ~12x forward earnings—half the S&P's mid-20s multiple and vs Eli Lilly at 24x—most bad news is baked in. Base case is mid-single-digit earnings growth plus a 4.5% dividend yield, for 8-9% annual returns over five years (max 10% incl dividend); if oral obesity drugs and phase-three amiritin succeed by 2028, returns could be 18-22% on a re-rating. He doesn't expect a double next year and cites Medicare pricing, patent expiries/generics, guidance down to 2030 and value-trap/innovation risk.

So my pick today is one of those companies which two years ago was the most valuable company in Europe. And pretty much everybody owned it. I don't know whether you owned it Stig, but pretty much a lot of people, a lot of ETFs, a lot of funds owned this company.

The analysts really loved it. But today that stock is down 40%. And from its 52- week high and it's trading roughly around 12 times forward earnings and basically everybody's saying parties over here.